कोशिश गोल्ड - मुक्त

“We are investing in larger cleanrooms, better QA vision systems, and more technical expertise”

BioSpectrum Asia

|

October 2020

Oliver Healthcare Packaging, one of the leading providers of sterile barrier flexible packaging for the global healthcare industry, emphasize on custom engineered design of Sterile Barrier System (SBS) to meet medical innovations and packaging technologies. Oliver Healthcare with its state-of-the-art manufacturing facility, expanding global SBS manufacturing footprint to Asian market. Mike Benevento, President & CEO, Oliver Healthcare Packaging, Princeton, New Jersey, USA, further elaborates on the critical role of SBS and its significance as integral part of Asia Pacific (APAC) MedTech industry. Edited excerpts;

- Hithaishi C Bhaskar

“We are investing in larger cleanrooms, better QA vision systems, and more technical expertise”

How do you assess the primacies in the development of sterile barrier systems (SBS)?

The aseptic operations at medical devices and pharmaceuticals industry comprises of unique challenges, opportunities, and most importantly the regulatory landscape. Those developing devices and drugs should engage packaging firms with dedicated design and technical expertise to design and develop medical sterile barrier systems. Organizations often undertake some form of in-house development of their SBS. This can be driven by many factors, including cost savings, and can be valuable in setting the stage. Yet, as part of regulatory due diligence, it is essential to note that there are complex SBS vulnerabilities that may be unknown to the product design team. Engaging with a medical packaging team can take early concepts to optimal solutions and success.

How do you foresee APAC healthcare SBS market?

The market in Asia Pacific (APAC) is well-positioned to serve its growing MedTech industry. An aging population, higher access to healthcare services, and growing disposable incomes fuel the APAC region’s market potential and opportunities. Today, a large portion of the market produces lower-end class I and II devices, but we also see growth in higher-end (class II and III) device manufacturing, which are typically more challenging from a packaging standpoint.

BioSpectrum Asia से और कहानियाँ

BioSpectrum Asia

BioSpectrum Asia

Collaborative R&D: Partnerships shaping the future of biopharma

Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.

time to read

2 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Quantum Computing: Future of diagnostics is being coded today

A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.

time to read

4 mins

BioSpectrum Asia Sep 2025

BioSpectrum Asia

First Pacific woman to serve as public health director in NZ

The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Hugel launches botulinum toxin Letybo in Malaysia

South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Australia designs smart wound monitor to improve chronic infection care

Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Revvity unveils innovative reagent technology to accelerate therapeutics development

US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

BioSpectrum Asia

Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B

Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education

HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.

time to read

1 min

BioSpectrum Asia Sep 2025

BioSpectrum Asia

Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI

Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.

time to read

1 min

BioSpectrum Asia Sep 2025

Translate

Share

-
+

Change font size